Irradiation Stent Placement Plus TACE for HCC and PVTT
Status:
Unknown status
Trial end date:
2021-11-10
Target enrollment:
Participant gender:
Summary
The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical
trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE
compared to sorafenib plus TACE in patients with advanced HCC accompanied by portal vein
tumor thrombosis. Patients will be randomized to receive either portal irradiation stent
placement plus TACE(Arm A) or Sorafenib plus TACE (Arm B).